Interaksi Buprenorfin dan nalokson dan Naltrekson
Buprenorfin dan nalokson dan Naltrekson: kedua label peresepan menandai kombinasi ini dengan bahasa yang paling tegas, seperti kontraindikasi, peringatan kotak hitam, atau instruksi untuk menghindarinya.
Jangan dikombinasikan tanpa arahan dokter yang meresepkan. Bahasa label di bawah ini adalah yang paling tegas yang digunakan FDA.
Apa kata label FDA
Dari label Buprenorfin dan nalokson (Buprenorphine and Naloxone) · berlaku sejak 2026-06-16
Buprenorphine and naloxone sublingual tablet is contraindicated in patients with a history of hypersensitivity to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported [see Warnings and Precautions (5.9) ] .
Hypersensitivity to buprenorphine or naloxone.
Use in Patients with Impaired Hepatic Function Buprenorphine/naloxone products are not recommended in patients with severe hepatic impairment and may not be appropriate for patients with moderate hepatic impairment.
However, buprenorphine/naloxone products are not recommended for initiation of treatment (induction) in patients with moderate hepatic impairment due to the increased risk of precipitated withdrawal.
If a CYP3A4 inducer is discontinued, consider buprenorphine and naloxone sublingual tablet dosage reduction and monitor for signs of respiratory depression.
Dari label Naltrekson (Naltrexone) · berlaku sejak 2026-01-30
Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids [see Warnings and Precautions ( 5.3 ) ] .
Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids (4) .
Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] .
Patients with current physiologic opioid dependence [see Warnings and Precautions ( 5.3 ) ] .
Patients in acute opioid withdrawal [see Warnings and Precautions ( 5.3 ) ] .
Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.
Buka di pemeriksaBukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.